Algiax’s Non-Opioid Pain Drug Shows Promise In Phase II
Topline results from Algiax’s AP-325 candidate for neuropathic pain are encouraging, but questions still remain about the drug’s claims to non-dependency and efficacy.
Topline results from Algiax’s AP-325 candidate for neuropathic pain are encouraging, but questions still remain about the drug’s claims to non-dependency and efficacy.